T1	Participants 59 98	cetuximab-associated acnelike eruption.
T2	Participants 315 345	cetuximab-related facial rash.
T3	Participants 354 434	In all, 24 patients with metastatic colorectal cancer with cetuximab facial rash
T4	Participants 1211 1255	patients with cetuximab-related facial rash.
